In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OUTLOOK 2021

Annual industry ranking and forecast

Opportunities For Medtech In Mental Health

Executive Summary

With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In Vivo explores transcranial magnetic stimulation systems that are being used to treat severe anxiety and depression, among other indications. As well as the skyrocketing use of telehealth, apps and light therapy for mental health indications.  

You may also be interested in...



Rock Health Reports Record Digital Health Funding Of $5.4Bn In H1 2020, Sees Potential For Record-Year Funding

Digital health funding is on track for the largest funding year ever amid the COVID-driven demand for telehealth and remote monitoring of patients. However, a large second wave of the pandemic could reverse that trend.

OCD Indication Approved For Brainsway TMS Device

US FDA used its de novo review pathway to approve Brainsway Ltd.’s Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder.

Happify Health Collaborates With Biogen To Support People Living With Multiple Sclerosis

Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV124573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel